Action 867 CHINA MEDICAL SYSTEM HOLDINGS LIMITED
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues China Medical System Holdings Limited

Actions

867

KYG211081248

Marché Fermé - Hong Kong S.E.
Autres places de cotation
 10:08:34 17/07/2024 		Varia. 5j. Varia. 1 janv.
6,75 HKD +4,17 % Graphique intraday de China Medical System Holdings Limited +6,13 % -51,23 %
25/06 China Medical System Holdings Limited achève le dosage du premier sujet de l'essai de transition de phase III de la crème de ruxolitinib dans la dermatite atopique en Chine CI
19/06 Bourse Zurich: séance en manque d'impulsion en perspective AW

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
China Medical System （867.HK） Reincluded in S&P Global Sustainability Yearbook （China Edition） and Maintained MSCI ESG “AA” Rating
China Medical System Completes Dosing of the First Subject in Phase III Bridging Trial of Ruxolitinib Cream in Atopic Dermatitis in China
China Medical System Holdings Limited Completes Dosing of the First Subject in Phase III Bridging Trial of Ruxolitinib Cream in Atopic Dermatitis in China
Cosmo's oral diagnostic drug Lumeblue receives approval of New Drug Application in China
China Medical System Gets Drug Registration Certificate for Lesion Visualization Drug in China
China Medical System: Innovative Drug Methylthioninium Chloride Enteric-coated Sustained-release Tablets Approved for Marketing in China
China Medical System Holdings Limited Announces Approval of Lumeblue® by NMPA for Enhanced Colorectal Lesion Detection
China Medical System Holdings Limited Approves Final Dividend for the Year Ended 31 December 2023
China Medical System: New Drug Application of Desidustat Tablets Accepted in China
China Medical System's Anti-Anaemia NDA Accepted in China
China Medical System Holdings Limited Announces New Drug Application of Desidustat Tablets Accepted in China
Zydus Lifesciences' Desidustat Tablets Get Nod from China Regulator
China Medical System Registers New Vitiligo Drug in Macau
China Medical System Holdings Limited commences an Equity Buyback for 245,198,851 shares, representing 10% of its issued share capital, under the authorization approved on April 28, 2023.
Incyte, China Medical System Sign Collaboration, License Agreement
CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast Asia
Incyte Corporation and China Medical System Holdings Limited Announce Collaboration and License Agreement for Povorcitinib, an Oral Jak1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia
China Medical System （867.HK）2023 Annual Results: Despite of the Temporary Financial Performance Pressure Fresh Catalysts Emerged from Successive Innovation Breakthroughs
China Medical System Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2023
China Medical System Holdings Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on About 23 May 2024
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action 867
  4. Actualités China Medical System Holdings Limited
  5. Autres langues